Abstract: The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Abstract: The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Abstract: Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.

Abstract: The present invention provides engineered models that recapitulate bone marrow, including the endosteal and vascular niches, and bone marrow diseases. The models can be implemented in many ways including, but not limited to, on a microfluidic device or microfluidic chip, a culture model in vitro, and as an implantable model in vivo. Also provided are methods of using these models, including high-throughput systems and in personalized medicine analysis. Also provided are devices for use in the provided bone marrow models, and kits that include at least one such device.

Abstract: A user equipment (UE) registers on a first Public Land Mobile Network (PLMN) and, while in an idle mode, receives a Multimedia Broadcast Multicast Services (MBMS) service. The UE determines whether to perform a periodic network reselection search for a higher priority PLMN while in the idle mode, wherein the UE determines whether to perform the periodic network reselection search based on reception of the MBMS service. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may interleave the periodic network reselection search with the reception of transmission bursts of the MBMS service, the search being performed on frequencies other than that of the MBMS transmission.

Abstract: Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.

Abstract: Diacylglycerol (DAG) plays a central role in both the synthesis of complex lipids and in intracellular signaling; diacylglycerol kinase (DGK) catalyzes the phosphorylation of DAG, which yields phosphatidic acid. A family of DGKs has been identified in multicellular organisms over the past few years, but the physiological function(s) of this diversity is not clear. One clue has come from the Drosophila DGK2, rdgA, since mutations in this gene cause retinal degeneration. The present invention relates to a novel DGK, designated DGK&igr;, which was isolated from human retina and brain libraries. DGK&igr; contains two cysteine-rich repeats, a region similar to the phosphorylation site domain of MARCKS, a conserved catalytic domain, and four ankyrin repeats at its C-terminus. By primary structure, DGK&igr; is most similar to human DGK&zgr; and Drosophila rdgA. A>12 kb mRNA for DGK&igr; was detected only in brain and retina among the tissues examined.